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ORIGINAL ARTICLE

Evidence that a lipolytic enzyme—hematopoietic-speciﬁc
phospholipase C-β2—promotes mobilization of hematopoietic
stem cells by decreasing their lipid raft-mediated bone marrow
retention and increasing the promobilizing effects of
granulocytes
M Adamiak1,4, A Poniewierska-Baran1,4, S Borkowska1, G Schneider1, A Abdelbaset-Ismail1, M Suszynska2, A Abdel-Latif2, M Kucia1,3,
J Ratajczak1 and MZ Ratajczak1,3
Hematopoietic stem/progenitor cells (HSPCs) reside in the bone marrow (BM) microenvironment and are retained there by the
interaction of membrane lipid raft-associated receptors, such as the α-chemokine receptor CXCR4 and the α4β1-integrin (VLA-4,
very late antigen 4 receptor) receptor, with their respective speciﬁc ligands, stromal-derived factor 1 and vascular cell adhesion molecule
1, expressed in BM stem cell niches. The integrity of the lipid rafts containing these receptors is maintained by the glycolipid
glycosylphosphatidylinositol anchor (GPI-A). It has been reported that a cleavage fragment of the ﬁfth component of the activated
complement cascade, C5a, has an important role in mobilizing HSPCs into the peripheral blood (PB) by (i) inducing degranulation
of BM-residing granulocytes and (ii) promoting their egress from the BM into the PB so that they permeabilize the endothelial barrier
for subsequent egress of HSPCs. We report here that hematopoietic cell-speciﬁc phospholipase C-β2 (PLC-β2) has a crucial role in
pharmacological mobilization of HSPCs. On the one hand, when released during degranulation of granulocytes, it digests GPI-A, thereby
disrupting membrane lipid rafts and impairing retention of HSPCs in BM niches. On the other hand, it is an intracellular enzyme required
for degranulation of granulocytes and their egress from BM. In support of this dual role, we demonstrate that PLC-β2-knockout mice are
poor mobilizers and provide, for the ﬁrst time, evidence for the involvement of this lipolytic enzyme in the mobilization of HSPCs.
Leukemia (2016) 30, 919–928; doi:10.1038/leu.2015.315

INTRODUCTION
Hematopoietic stem/progenitor cells (HSPCs) express the
chemokine receptor CXCR4 and the very late antigen 4 receptor
(VLA-4, also known as α4β1-integrin) on their cell surface and are
retained in the bone marrow (BM) niches by interaction of these
receptors with their respective ligands, the α-chemokine stromal
cell-derived factor 1 (SDF-1) and vascular adhesion molecule 1
(VCAM-1, also known as CD106), expressed by cells in the BM
microenvironment (e.g., by osteoblasts and ﬁbroblasts).1–6 Mobilization studies using small-molecule antagonists of CXCR4 or
VLA-4 indicate the importance of both axes in retention of HSPCs
in the BM microenvironment.1–7 Moreover, evidence has accumulated that both receptors need to be incorporated into membrane
lipid rafts for optimal function6–11 and that a glycolipid,
glycosylphosphatidylinositol anchor (GPI-A), has a pivotal role in
maintaining the integrity of cell-surface membrane lipid
rafts.6,8,11,12 In support of this notion, patients suffering from
paroxysmal nocturnal hemoglobinuria, in which HSPCs do not
express GPI-A on the cell surface, show a profound defect in HSPC
retention in BM niches.6,8

GPI-A can also be removed from cell membranes by exposure to
the lipolytic enzyme phospholipase C (PLC), which, if released from
the cells, affects GPI-A by enzymatic digestion and thus disrupts
lipid raft integrity.6 On the one hand, PLC is an intercellular enzyme
that is released from cells during inﬂammation,13–15 and thus may
affect cell-surface expression of proteins that are closely associated
with GPI-A, including a truncated form of VCAM-1, the complement
inhibitors CD55 and CD59, and uPAR.6,16,17 On the other hand, as an
intracellular enzyme, PLC is involved in the chemotactic response of
leukocytes to the cleavage fragment of the ﬁfth protein component
of the complement cascade (C5a).18,19 Overall, the PLC family of
enzymes consists of 13 members split between six subfamilies,
including the PLC-δ (1, 3, 4), -β (1–4), -γ (1, 2), -ε, -ζ and -η (1, 2)
isoforms. Among these isoforms, PLC-β2 is unique in being
predominantly expressed in hematopoietic-speciﬁc enzyme.18–20
HSPCs are mobilized from BM niches into the peripheral blood
(PB) after administration of the cytokine granulocyte colonystimulating factor (G-CSF) or the small-molecule antagonist of the
CXCR4 receptor AMD3100.1–6,21–23 Administration of these drugs
activates several pathways in the BM microenvironment, including
the complement cascade. In particular, activation of the distal part
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of the complement cascade releases C5a, which is processed to its
long-lasting derivative desArgC5a. C5-deﬁcient mice are poor
mobilizers, which supports an important role for C5a and desArgC5a
in the egress of HSPCs from the BM into the PB.24 The explanation
for this ﬁnding is that both C5 cleavage fragments induce
degranulation of BM-residing granulocytes, which releases
proteolytic enzymes and promotes egress of these cells from
the BM into the PB. These cells also permeabilize the endothelial
barrier for subsequent egress of HSPCs.24,25 As mentioned above,
C5a interaction with the C5a receptor on granulocytes activates
intracellular PLC-β2-mediated signaling.18,19
Based on the potential dual role of PLC-β2 in the mobilization
process, including (i) its potential extracellular effect as an enzyme
that targets GPI-A and impairs lipid raft integrity and (ii) its role in
intracellular C5a-mediated signal transduction, which leads to
degranulation of granulocytes, we performed mobilization studies
in PLC-β2-knockout (PLC-β2-KO) mice.
We demonstrate here for the ﬁrst time that PLC-β2-deﬁcient
mice are poor mobilizers and that this lipolytic enzyme is involved
in the mobilization process by (i) disrupting lipid raft integrity and
(ii) enabling C5a-mediated release of proteolytic enzymes by
granulocytes as well as their chemotactic migration in response to
a C5a gradient between BM and PB.

Lipid raft detection

Six-week-old C57BL/6J wild-type mice (WT) and B6.129S1-Plcβ2tm1Dwu/J
PLC-β2-KO mice of both sexes were used in our experiments. Mice from
the Jackson Laboratory (Bar Harbor, ME, USA) were randomly divided into
two groups of each sex. Animal studies were approved by the Animal Care
and Use Committee of the University of Louisville (Louisville, KY, USA).

Murine tibias and femurs were ﬂushed, and BM-derived MNCs were
separated via Ficoll-Paque. Murine CD34–LSK (Lin–Sca-1+c-Kit+CD34–) cells
were puriﬁed by using ﬂuorescence-activated cell sorting (FACS) from
BM-derived MNCs using the following lineage marker-speciﬁc antibodies:
PE-anti-TCR γδ, clone GL3; PE-anti-CD11b, clone M1/70; PE-anti-TCR β-chain,
clone H57-597; PE-anti-CD45R/B220, clone RA3-6B2; PE-anti-TER-119/erythroid cells, clone TER-119; PE-anti-Ly-6G and Ly-6C, clone RB6-8C5; PE-Cy5anti-Ly-6A/E (Sca-1), clone E13-161.7; ﬂuorescein isothiocyanate (FITC)-antiCD117 (c-Kit), clone 2B8; biotin-anti-CD34, clone HM34; and APC-streptavidin). Human CD34+ cells were obtained from cord blood after Ficoll-Paque
separation, and subsequent isolation of CD34+ cells was performed using the
CD34 MicroBead Kit, human (Miltenyi Biotec, San Diego, CA, USA). Highly
puriﬁed human HSC (Lin–CD38–CD45RA–CD34+CD90+CD49f+) and MPP
(Lin–CD38–CD45RA–CD34+CD90–CD49f–) fractions were isolated by FACS28
using the following lineage marker-speciﬁc antibodies: FITC-anti-CD235a,
clone GA-R2 (HIR2); FITC-anti-CD2, clone RPA-2.10; FITC-anti-CD3, clone
UCHT1; FITC-anti-CD14, clone M5E2; FITC-anti-CD16, clone 3G8; FITC-antiCD19, clone, HIB19; FITC-anti-CD24, clone ML5; FITC-anti-CD56, clone
NCAM16.2; FITC-anti-CD66b, clone G10F5; PerCP-anti-CD38, clone HB-7;
PE-anti-CD90 (Thy1), clone 5E10; PE-Cy7-anti-CD49f, clone GoH3; APC-Cy7anti-CD45RA, clone HI100; and APC-anti-CD34, clone 581/CD34. Brieﬂy, cells
were plated on poly-L-lysine-coated plates overnight, then incubated with
phosphatidylinositol-speciﬁc phospholipase C (Sigma-Aldrich) for 1 h,
washed and ﬁxed in 3.7% paraformaldehyde. The cholera toxin B subunit
conjugated with FITC (Sigma-Aldrich) was applied to detect the ganglioside
GM1, and mouse monoclonal anti-hCXCR4 IgG antibody (R&D Systems) and
Alexa Fluor 594 goat anti-mouse IgG antibody (Invitrogen) were applied to
detect CXCR4. VLA-4 was stained with monoclonal rat anti-mouse integrin α4
(CD49d) antibody (EMD Millipore, Billerica, MA, USA) and Alexa Fluor 594.
Stained cells were examined, and images were generated using a FluoView
FV1000 laser-scanning confocal microscope (Olympus America Inc., Center
Valley, PA, USA).8

Isolation of Gr-1+ cells

Transwell migration assay

Gr-1+ cells were isolated from the BM of adult male or female mice. Brieﬂy,
the BM was ﬂushed from femurs, and the population of total nucleated
cells was obtained after lysis of red blood cells (RBCs) using 1 × BD Pharm
Lyse buffer (BD Pharmingen, San Jose, CA, USA). Cells were subsequently
stained with phycoerythrin (PE)-anti-Gr-1 antibody (anti-Ly-6G and Ly-6C,
clone RB6-8C5) or with PE-anti-CD11b antibody (clone M1/70) for 30 min in
medium containing 2% fetal bovine serum. Cells were then washed,
resuspended in RPMI-1640 medium and sorted using a Moﬂo XDP cell
sorter (Beckman Coulter, Indianapolis, IN, USA) as populations of
granulocytes (SSChighGr-1+) or monocytes (SSClowCD11b+).26,27

BM-derived Gr-1+ cells from WT and PLC-β2-KO mice were resuspended in
assay medium (RPMI-1640 plus 0.5% BSA). Assay medium (650 μl) alone
and containing C5a (140 ng/ml) or desArgC5a (140 ng/ml) purchased from
Calbiochem (La Jolla, CA, USA) was added to the lower chambers of a
Costar Transwell 24-well plate (Corning Costar, Cambridge, MA, USA).
Aliquots of cell suspension (1 × 106 cells per 100 μl) were loaded onto the
upper chambers with 5 μm pore ﬁlters, and then incubated for 3 h (37 °C,
5% CO2). Cells from the lower chambers were harvested and scored by
FACS analysis.24,29

Measuring PLC activity

Signal-transduction studies

MATERIALS AND METHODS
Animals

+

Gr-1 cells were resuspended in medium RPMI-1640 plus 0.5% bovine
serum albumin (BSA, 2 ml cells per 400 μl medium) and incubated
overnight at 37 °C. Subsequently, cells were stimulated by adding G-CSF
(100 ng/ml), AMD3100 (3 μM), C5a (1 μM) or desArgC5a (140 ng/ml) and
incubated for 6 h at 37 °C. The cells were centrifuged, and conditioned
media (CM) were collected and diluted (1:5). PLC activity was measured
using the Amplex Red Phospholipase C Assay Kit (A12218; Invitrogen,
Carlsbad, CA, USA), according to the manufacturer's protocol, by
measuring the ﬂuorescence in a ﬂuorescence microplate reader (Beckman
Coulter DTX 880 Multimode Detector, Beckman Coulter) using excitation
in the range of 530–560 nm and emission detection at ~ 590 nm.

FACS analysis of GPI-anchored proteins
The enzymatic action of phosphatidylinositol-speciﬁc phospholipase C
(Sigma-Aldrich, St Louis, MO, USA) results in the release of GPI-anchored
proteins, such as VCAM-1, uPAR, CD55 and CD59, from the cell membranes.
BM stromal cells and BM mononuclear cells (MNCs) were incubated with
phosphatidylinositol-speciﬁc phospholipase C (5 or 100 mU/ml) for 3 h
at 37 °C. Alexa Fluor 647-conjugated anti-mouse CD106 clone 429
(BioLegend, San Diego, CA, USA), PE-conjugated anti-mouse uPAR clone
109801 (R&D Systems, Minneapolis, MN, USA), PE-conjugated hamster antimouse CD55 and anti-mouse CD59a clone 7A6 (BD Biosciences, San Jose,
CA, USA) were applied to detect GPI-anchored proteins.
Leukemia (2016) 919 – 928

Sorted Gr-1+ cells from WT and PLC-β2-KO mice were incubated overnight
at 37 °C to induce quiescence. Next, the cells were stimulated with either
RPMI-1640 plus 0.5% BSA alone or with the complement promobilizing
factors C5a (140 ng/ml) or desArgC5a (140 ng/ml) for 2 min at 37 °C and then
lysed using RIPA lysis buffer supplemented with protease and phosphatase
inhibitors (Santa Cruz Biotech, Dallas, TX, USA). The extracted proteins were
then separated on a 4–12% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis gel, and the fractionated proteins were transferred to a
polyvinylidene ﬂuoride membrane. Phosphorylated intracellular kinase
p42/44 mitogen-activated protein kinase (phospho-p42/44 MAPK) and
phospho-AKT were detected with phospho-speciﬁc p42/44 MAPK (clone
9101) and phospho-speciﬁc AKT (Ser473; clone 9271) rabbit polyclonal
antibodies (Cell Signaling, Danvers, MA, USA), respectively. Horseradish
peroxidase (HRP)-conjugated goat anti-rabbit IgG was used as a secondary
antibody (Santa Cruz Biotech). To evaluate protein loading, blots were
subjected to stripping using stripping buffer (Thermo Scientiﬁc, Waltham,
MA, USA) and then reprobing with appropriate anti-rabbit p42/44 MAPK
(clone 9102) and AKT (clone 9272) monoclonal antibodies (both from
Cell Signaling). All membranes were treated with an enhanced chemiluminescence (ECL) reagent (Amersham Life Science, Little Chalfront, UK),
dried and subsequently exposed to ﬁlm (Hyperﬁlm, Amersham Life
Sciences). For band visualization, an automatic ﬁlm processor supplied
with fresh, warm developer and ﬁxer solutions was used.24,29
© 2016 Macmillan Publishers Limited
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Degranulation assay

Fibronectin cell adhesion assay

Gr-1+ cells from WT and PLC-β2-KO mice were resuspended in medium
RPMI-1640 plus 0.5% BSA (2 ml cells per 400 μl medium) and incubated
overnight at 37 °C. Subsequently, cells were stimulated by adding C5a
(140 ng/ml), desArgC5a (140 ng/ml) or medium alone as control and then
incubated for 6 h at 37 °C. Cells were centrifuged, and CM were collected.
Myeloperoxidase (MPO) activity was determined using 3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich) as described.30 Brieﬂy, 20 μl samples
were combined with 100 μl of 3,3′,5,5′-tetramethylbenzidine substrate
solution, and the plate was incubated at 37 °C for 20 min. The reaction was
stopped by adding 50 μl of 1 M H2SO4, and absorption was measured at
450 nm to estimate myeloperoxidase activity. Elastase activity was
measured using the EnzChek Elastase Assay Kit, according to the
manufacturer’s instructions (Life Technologies, Carlsbad, CA, USA). Brieﬂy,
100 μl fresh sample was incubated with 100 μl substrate solution (with
25 μg/ml DQ elastin) for up to 4 h at room temperature in the dark, and the
resulting ﬂuorescence was recorded at 515 nm emission following 505 nm
excitation. All activity assays were performed in triplicate in 96-well
microtiter plates and analyzed with a Beckman Coulter DTX 880 Multimode
Detector. Results are shown as a percentage of control samples, P ⩽ 0.05.

BM MNCs were made quiescent for 3 h with RPMI-1640 plus 0.5% BSA
medium and incubation with phosphatidylinositol-speciﬁc phospholipase
C (100 and 1 U/ml) for 10, 30 or 60 min. Subsequently, cell suspensions
(15 × 104/100 μl) were added directly to 96-well plates coated with
ﬁbronectin (10 μg/ml) with or without SDF-1 (300 ng/ml) for 15 min at
37 °C. The wells were then washed of non-adherent cells, and all adherent
cells were counted using an inverted microscope.8

In vivo mobilization studies
Mice (WT and PLC-β2-KO) were mobilized with G-CSF (short incubation,
3 days; long incubation, 6 days; both 100 μg/kg per day, subcutaneous
injection) and AMD3100 (1 day, 5 mg/kg, subcutaneous injection). At 6 h
after the last G-CSF injection or 1 h after AMD3100 injection, the mice were
bled from the retro-orbital plexus for plasma and hematology analysis, and
PB was obtained from the vena cava (with a 25-gauge needle and 1 ml
syringe containing 250 U heparin). MNCs were obtained by hypotonic lysis
of RBCs in BD Pharm Lyse buffer (BD Biosciences) as described.31,32 PLC
activity in mouse mobilized plasma and CM derived from BM after
AMD3100 and G-CSF injection was evaluated. Plasma and CM were diluted
1:500 and 1:5, respectively. A phospholipase C assay was performed
according to the Amplex Red Phospholipase C Assay Kit protocol.

Clonogenic in vitro assay
After RBCs from PB were lysed (Pharm Lyse buffer; BD Biosciences),
nucleated cells from PB were subsequently washed two times and used for
a CFU-GM assay. The cells were counted and resuspended in human
methylcellulose base media provided by the manufacturer (R&D Systems),
supplemented with 25 ng/ml recombinant murine granulocyte macrophage colony-stimulating factor (mGM-CSF) and 10 ng/ml recombinant
murine interleukin-3 (Millipore, Billerica, MA, USA). Cultures were incubated
for 7 days and then scored for the number of CFU-GM colonies under an
inverted microscope. We cultured 1 × 106 PB MNCs per dish, and the ﬁnal
results were recalculated based on the number of PB MNCs per 1 μl of PB.
Each clonogenic test was performed in duplicate. To evaluate the number
of clonogenic progenitor cells, BM MNCs were supplemented with
erythropoietin (5 U/ml; Stem Cell Tech., Vancouver, BC, Canada) plus stem
cell factor (5 ng/ml) and resuspended in methylcellulose base medium (for
determining the number of burst-forming unit-erythroid), supplemented
with thrombopoietin (100 ng/ml) plus murine interleukin-3 (10 ng/ml), and
the resuspended plasma clots used for determining the number of
CFU-megakaryocytes. The CFU-GM assay was performed as above. Cultures
were incubated for 7 days (37 °C, 95% humidity and 5% CO2), at which
time they were scored under an inverted microscope for the number of
each type of colony as described.29

Statistical analysis
Generation of radiation chimeras
Twenty-four hours after lethal irradiation (1000 cGy), WT and PLC-β2-KO
female mice were transplanted through the retro-orbital plexus with
5 × 106 BM MNCs from PLC-β2-KO or WT mice. Animals that had
undergone transplantation were allowed to recover for 5 weeks, after
which chimeras were mobilized and analyzed in the same way as
described above for in vivo mobilization studies.

PB parameter counts
To obtain leukocyte and RBCs counts, 50 μl of PB was taken from the retroorbital plexus of the mice into microvette EDTA-coated tubes (Sarstedt Inc.,
Newton, NC, USA) and run within 2 h of collection on a HemaVet 950FS
hematology analyzer (Drew Scientiﬁc Inc., Oxford, CT, USA).24,31

FACS analysis
The following monoclonal antibodies were used to perform staining of
Lin–/Sca-1+/c-Kit+ (SKL) cells and Lin–/Sca-1+/CD45+ (HSCs): FITC–anti-CD117
(also known as c-Kit, clone 2B8; BioLegend) and PE-Cy5-anti-mouse Ly-6 A/E
(also known as Sca-1, clone D7; eBioscience, San Diego, CA, USA). All
anti-mouse lineage markers (Lin) were purchased from BD Biosciences: antiCD45R/B220 (clone RA3-6B2), anti-Ter-119 (clone TER-119), anti-CD11b (clone
M1/70), anti-T-cell receptor β (clone H57-597), anti-Gr-1 (clone RB6-8C5), antiTCRγδ (clone GL3) and anti-CD45 (clone 30-F11) and conjugated with PE as
described.24,29,31,32 All monoclonal antibodies were added at saturating
concentrations, and the cells were then incubated for 30 min on ice, washed
twice, resuspended in RPMI-1640 plus 2% fetal bovine serum, and analyzed
with an LSR II ﬂow cytometer (BD Biosciences, San Diego, CA, USA).

Evaluation of HSPC mobilization
For evaluation of circulating colony-forming unit-granulocyte/macrophage (CFU-GM) and SKL cells, the following formulas were used:
(number of white blood cells (WBCs) × number of CFU-GM colonies)/
number of WBCs plated = number of CFU-GM per ml of PB; and (number
of WBCs × number of SKL cells)/number of gated WBCs = number of SKL
cells per μl of PB.24,29,31,32
© 2016 Macmillan Publishers Limited

All results are presented as mean ± s.d. Statistical analysis of the data was
carried out using Student's t-test for unpaired samples, with P ⩽ 0.05
considered signiﬁcant.

RESULTS
PLC becomes activated in BM during HSPC mobilization
It has been reported that PLC is released from HSPCs during
inﬂammation and that its extracellular concentration increases in
body ﬂuids.13–15 As mobilization of HSPCs is part of the innate
immunity inﬂammatory response,4 we became interested in
whether PLC is released from cells in response to G-CSF- or
AMD3100-induced mobilization. To address this question, we
measured PLC activity in blood plasma and in CM from cells
recovered from the BM cavities of mobilized animals and
observed an increase in PLC activity (Figure 1a).
Next, based on evidence that C5a activates granulocytes in a
PLC-dependent manner, we sorted the BM Gr-1+ cells and
stimulated them with both C5 cleavage fragments, C5a and
desArgC5a, as well as with G-CSF and AMD3100. Figure 1b
demonstrates that, upon stimulation, BM-puriﬁed Gr-1+ cells
isolated from BM secrete PLC into the culture medium. Interestingly, we also observed some differences in the PLC level detected
in preparations of Gr-1+ cells isolated from male and female mice.
As shown in Figure 1b, female mice secreted more PLC-β2 than
males upon stimulation.
Finally, we performed dose–response studies on granulocytes
(SSChighGr-1+ cells) and monocytes (SSClowCD11b+ cells) puriﬁed
from murine BM.26,27 Cells were stimulated (Figure 1c) with
increasing doses of G-CSF (left panel) or AMD3100 (right panel),
and PLC-β2 was detected by enzyme-linked immunosorbent
assay. It can be seen that PLC-β2 activity was detected in CM
harvested from granulocytes.
Leukemia (2016) 919 – 928
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Figure 1. PLC activation in response to promobilizing factors. (a) PLC activity was measured in plasma (left panel) and BM cell CM (right panel)
from the BM of WT male and female mice mobilized with G-CSF or AMD3100. (b) PLC activity in CM from Gr-1+ cells sorted from female and
male WT mice. BM was incubated for 6 h with G-CSF, AMD3100, C5a or desArgC5a. (c) Dose–response effect of promobilizing factors on PLC
activation. PLC activity in CM from granulocyte and monocyte cells sorted from BM. BM-isolated granulocytes or macrophages were
incubated for 6 h with G-CSF (10, 50, 100 and 500 ng/ml, left panel) or AMD3100 (0.3, 1, 3, 10 and 30 μM, right panel). The assay was performed
according to the Amplex Red Phospholipase C Assay Kit protocol. Data from two separate experiments are pooled together and compared
with untreated controls. *P ⩽ 0.05 and **P ⩽ 0.005.

PLC targets several molecules involved in retention of HSPCs in
the BM
Based on the ﬁnding that PLC is released during mobilization from
granulocytes (Figure 1a), we focused on potential GPI-A+ targets for
this enzyme, including the murine short isoform of VCAM-1, uPAR
and the complement cascade inhibitors CD59 and CD55.6,16 As
shown in Figure 2a, exposure of BM-derived murine mesenchymal
stromal cells to PLC resulted in dose-dependent removal from the
cell membrane of the GPI-A+ truncated form of VCAM-1 and uPAR
(Figure 2a, left panel). Similarly, exposure of BM MNCs to PLC led to
a decrease in the expression of GPI-A+ cell-surface complement
inhibitors CD59 and CD55 (Figure 2a, right panel).
Moreover, as the glycolipid GPI-A is required for the proper
function of lipid rafts,6,8,11,12 we exposed murine CD34–LSK cells
enriched for HSPCs to PLC and evaluated the effect on lipid raft
integrity (Figure 2b). We found that murine CD34–LSK cells exposed
to PLC display defective lipid raft formation, which is crucial for
CXCR4- and VLA-4-mediated retention of HSPCs in the BM.1–7
Similar results were obtained with human Lin–CD38–CD45RA–CD34+
CD90–CD49f– cells (Supplementary Figure 1). Furthermore, our
adhesion experiments demonstrated that, if exposed to PLC, murine
Sca-1+ cells show defective adhesion to mesenchymal stromas or
immobilized SDF-1 (Supplementary Figure 2).
This part of our work indicates that, as an extracellular enzyme
released pharmacologically to induce mobilization, PLC perturbs
the integrity of membrane lipid rafts and thus may affect retention
of HSPCs in their BM niches.
Leukemia (2016) 919 – 928

Defect in C5a- and desArgC5a-mediated degranulation and
chemotactic response in PLC-β2 granulocytes
Based on reports that hematopoietic cell-speciﬁc PLC (PLC-β2)
is involved in C5a signaling,18,19 we became interested in the
role of PLC-β2 in C5a- and desArgC5a-mediated responses of
murine BM-derived Gr-1+ leukocytes. These cells are the ﬁrst to
be mobilized into the PB and have a role in permeabilization of
the endothelial–BM barrier to pave the way for subsequent
egress of HSPCs.21,24,25
To address this issue, we evaluated the chemotactic responsiveness to C5a and desArgC5a gradients of murine BM-derived
Gr-1+ cells isolated from the BM of WT and PLC-β2-KO
mice (Figure 3a). As shown, we found impaired chemotactic
responsiveness of these cells in a Transwell migration assay,
which was supported by signal-transduction studies in which we
observed a severe reduction in MAPK p42/44 phosphorylation in
Gr-1+ cells from PLC-β2-KO animals (Figure 3b). This result was
corroborated by the results of a degranulation assay performed
in Gr-1+ cells isolated from WT and PLC-β2-KO mice stimulated
with C5a or desArgC5a (Figure 3c). We found that the release of
myeloperoxidase and elastase from PLC-β2-KO Gr-1+ cells was
signiﬁcantly impaired.
Based on this ﬁnding, we conclude that PLC-β2 is involved as an
intracellular enzyme in degranulation and release of proteolytic
enzymes, as well as in normal migration and egress of
granulocytes from the BM into the PB.
© 2016 Macmillan Publishers Limited
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Figure 2. Impact of PLC on GPI-A+ proteins expressed on BM cells. (a) Expression of VCAM-1 and uPAR receptors (left panel) on BM MNCs after
PLC treatment (5–100 mU/ml) and cell-surface expression of membrane complement regulators CD55 and CD59 on BM MNCs (right panel)
after PLC treatment (100 mU/ml). Data from three separate experiments are pooled together and compared with untreated controls. *P ⩽ 0.05
and **P ⩽ 0.005. (b) Defective lipid raft formation in murine BM-puriﬁed CD34–LSK cells. Representative images of CD34–LSK cells sorted from
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but not in CD34–LSK cells after PLC treatment.

PLC-β2-deﬁcient mice are poor G-CSF and AMD3100 mobilizers
Based on the above observations, we moved to a murine model of
PLC-β2 deﬁciency and used PLC-β2-KO animals. Supplementary
Figure 3 shows that PLC-β2-KO mice have normal PB cell counts
(Supplementary Figure 3A), RBC parameters (Supplementary
Figure 3B) and number of BM-residing HSCs (Supplementary
Figure 3C) and clonogenic progenitors (Supplementary Figure 3D)
compared with WT animals under steady-state conditions. At the
same time, we did not observe any sex-dependent differences.
© 2016 Macmillan Publishers Limited

Next, we performed in vivo mobilization experiments. As we had
observed some sex differences in the release of PLC during the
mobilization process (Figure 1b), we used both female and male PLCβ2− / − animals in our experiments. Figure 4 shows that PLC-β2-KO
mice had impaired day 3 G-CSF- (Figure 4a) and AMD3100-induced
mobilization (Figure 4b). Moreover, despite differences in PLC release
form Gr-1+ cells (Figure 1b), we did not observe any sex-related
differences in egress of HSPCs from the BM into the PB. Similar
results were obtained with PLC-β2-KO mice after G-CSF-induced
mobilization was prolonged to 6 days (Supplementary Figure 4).
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+

However, PLC-β2 has been reported to be hematopoietic
cell-speciﬁc. To exclude the possibility that the defect observed in
PLC-β2− / − mice on mobilization could also somehow be microenvironment-dependent, we created hematopoietic chimeras by
transplanting BM cells from PLC-β2− / − mice into WT animals and
vice versa. After chimeras were established, the mice were
mobilized 5 weeks later by treatment with G-CSF or AMD3100.
Figure 5 shows that WT chimeric mice transplanted with PLC-β2− / −
BM cells showed defective short- and long-term mobilization
induced by G-CSF (Figures 5a and b) and AMD3100 (Figure 5c). At
the same time, no mobilization defect was observed in PLC-β2− / −
mice reconstituted with WT BM cells. This result excludes any
potential involvement of residual PLC-β2 activity in nonhematopoietic tissues.
DISCUSSION
The salient observation of our study is that optimal mobilization of
HSPCs requires activation of hematopoietic-speciﬁc PLC-β2. This
lipolytic enzyme has an important role in this process by
regulating (i) the intracellular promobilizing functions of Gr-1+
cells and (ii) extracellular functions involving enzymatic perturbation of membrane lipid raft integrity, which is required for proper
function of the CXCR4 and VLA-4 receptors and BM retention of
HSPCs in their BM niches. This dual mechanism was supported by
Leukemia (2016) 919 – 928

showing that PLC-β2 mice are poor mobilizers, despite the fact
that under steady-state conditions these animals have normal PB
cell counts and normal BM hematopoiesis.19
The mechanism of pharmacologically induced mobilization of
HSPCs as a means to obtain stem cells for hematopoietic
transplants is still not fully understood. Several signaling pathways
regulating adhesion and migration of stem cells and regulating
BM hematopoietic niche integrity, including Rac-1 and Rac-2 GTPases,9–11 glycogen synthase kinase-3β,33 cAMP-induced phosphokinase-ζ34 and PGE2,35 have been proposed to promote retention
of HSPCs in the BM and their mobilization. Similarly, different
types of BM cells have been proposed to have a crucial role in this
process, including osteoblasts, osteoclasts,1,36–38 osteomacs,1,38
nestin+ mesenchymal stromas,39 CXCL12-abundant reticular
cells,40 granulocytes41 and monocytes.42
Moreover, while the proretention function of osteoblasts,
CXCL12-abundant reticular cells or nestin+ mesenchymal stromas
is acknowledged, the role of osteoclasts in mobilization of HSPCs
is still somehow controversial.37,43,44 Furthermore, as reported,
mice with knockout of multiple proteolytic enzymes, including
matrix metalloproteinase-9, matrix metalloproteinase-2, cathepsin
G and elastase, mobilize HSPCs in a similar manner as WT control
littermates.45 This ﬁnding suggests that deﬁciency in these
enzymes is compensated by others such as, for example, CD26
(also known as dipeptidylpeptidase-4). Another candidate enzyme
© 2016 Macmillan Publishers Limited
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is cathepsin K, which is expressed, for example, by osteoclasts,46
and direct mobilization studies in cathepsin K-KO mice could
answer this question.
For several years our group has been investigating the role of
innate immunity, including the complement cascade,4,24,47,48 coagulation cascade and ﬁbrinolytic cascade,31 in pharmacologically
induced HSPC mobilization, as we envision that this process is
related to the normal response of BM and the hematopoietic system
to stress situations seen in inﬂammation or tissue/organ injuries.4,36
Pharmacologically induced mobilization can be achieved after
administration of G-CSF or the CXCR4 antagonist AMD3100.1–6,21–23
The ﬁrst and most important step in this process is detachment of
HSPCs from the stem cell niches in the BM, where they are anchored
by the ligands SDF-1 and VCAM-1, which are expressed in these
niches. These ligands interact with the CXCR4 and α4β1-integrin
(VLA-4) receptors, respectively, expressed on the surface of HSPCs.
Both CXCR4 and VLA-4 are cell membrane lipid raft-associated
receptors, and their presence in lipid rafts is essential to their optimal
biological function.2,6,8–11 Cell membrane lipid raft integrity is governed
by GPI-A, which is a substrate for the lipolytic enzyme PLC.6,8,11,16 It is
© 2016 Macmillan Publishers Limited

widely accepted that an important role in pharmacological mobilization is played by induction of a proteolytic microenvironment in the
BM because of the release of proteolytic enzymes from granulocytes
and monocytes that digest proteins of the BM retention axes for
HSPCs (e.g., SDF-1–CXCR4 and VCAM-1–VLA-4).49
Here, for the ﬁrst time, we propose a novel mechanism in which,
in addition to proteolytic enzymes, lipolytic enzymes such as PLC
are released in the BM during the mobilization process, and a
lipolytic microenvironment in the BM is created. The phenomenon
of PLC release from cells during inﬂammation has been described
in several pathological situations, such as inﬂammation, brain
damage or cardiovascular complications,13–15,50,51 but so far it has
not been recognized during pharmacologically induced mobilization of HSPCs. Based on the results reported in this paper, we have
to consider the possibility that the mobilization process not only
induces a proteolytic49 but also a lipolytic microenvironment in
the BM. As demonstrated in our work, PLC released from Gr-1+
cells provides the basis for a novel mechanism promoting egress
of HSPCs from the BM into the PB. This mechanism is based, on
the one hand, on PLC-dependent digestion of GPI-A, leading to
Leukemia (2016) 919 – 928
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disintegration of lipid rafts, which results in perturbed CXCR4- and
VLA-4-mediated retention of HSPCs in BM niches. An important
role for lipid rafts in retention of HSPCs in the BM supports the
concept of enhanced release of HSPCs into the PB in patients
suffering from paroxysmal nocturnal hemoglobinura, a disorder in
which HSPCs acquire a GPI-A mutation.6,8,16 Our results also
explain in a novel way the increase in the soluble uPAR level that
is observed in experimental and clinical mobilization.6,17,52 As
uPAR is closely associated with a GPI-A fragment,6,17 it becomes
an easy substrate for PLC and thus is released from the cells.
Supporting evidence indicates that mobilizing agent-activated
complement cascade and C5 cleavage fragments (C5a and desArgC5a)
trigger egress of cells from the BM into the PB.6,24,25,31,32 To explain
this observation, both of these molecules, also known as anaphylatoxins, are potent stimulators of degranulation and are chemoattractants of granulocytes and monocytes.6,24,25,31,32 We have proposed
that mobilization-induced C5a/desArgC5a levels in PB chemoattractant
granulocytes and monocytes, and egress of these cells from the BM
into the PB facilitates subsequent egress of HSPCs.4,24,25
As reported previously, C5 deﬁciency,24 lack of granulocytes41
or a compromised function of monocytes42 all result in impaired
egress of HSPCs from the BM into the PB. Our results reported in
this paper support a promobilization link between C5a/desArgC5a
signaling, PLC-β2 and granulocyte function. PLC-β2 is required for
normal function of Gr-1+ cells, as we have shown that Gr-1+ cells
Leukemia (2016) 919 – 928

from PLC-β2-KO mice respond very poorly to C5a/desArgC5a
stimulation in degranulation assays and show impaired migration
in response to C5 cleavage fragments. This defective responsiveness of Gr-1+ cells to C5a and desArgC5a is one of the reasons why
PLC-β2-KO mice are poor mobilizers, as reported in our study.
Therefore, our results provide, for the ﬁrst time, evidence that not
only are proteolytic enzymes, such as MMP-9, MMP-2, cathepsin G,
elastase, and CD26, activated during mobilization of HSPCs5,45,46,49
but lipolytic enzymes such as PLC-β2 are also involved in this
process, which was not previously appreciated. We envision that, in
addition to PLC-β2, other enzymes also affect expression of the
bioactive lipid sphingosine-1-phosphate (S1P). As recently demonstrated, mice with decreased activity of S1P kinase type 1 in BM,
resulting in low BM expression of S1P, have a defect in retention of
HSPCs in BM.53 Similarly, we expect that a high level of activity of
the S1P-degrading enzyme S1P lyase has a similar effect. The
importance of PLC-β2 and potentially other lipolytic enzymes in the
retention of stem cells in BM may better explain why mice deﬁcient
in several proteolytic enzymes still mobilize HSPCs into the PB.45
Figure 6 summarizes our current understanding of the role of PLCβ2 in retention and egress of HSPCs. As demonstrated, intracellular
PLC-β2 is involved in C5a/desArgC5a signaling-mediated degranulation of Gr-1+ cells and chemotactic responsiveness of these cells to a
PB–BM gradient of both C5 cleavage fragments. This process then
facilitates egress of HSPCs across the BM–PB endothelial barrier.
© 2016 Macmillan Publishers Limited
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PLC-β2 released from granulocytes also has an additional function as
an extracellular enzyme that disrupts membrane lipid rafts and thus
impairs retention of HSPCs in BM niches. All these biological effects
of PLC-β2 together facilitate egress of cells into the PB.
In conclusion, we have established for the ﬁrst time that, in
addition to proteolytic enzymes, the lipolytic enzyme PLC-β2 is
upregulated in the BM microenvironment during pharmacologically
induced mobilization and promotes mobilization of HSPCs by
inducing the promobilization function of Gr-1+ cells and perturbing
BM retention of HSPCs. These results also support an important role
for GPI-A-dependent proteins in the retention of HSPCs in BM
niches and shed more light on C5a/desArgC5a-mediated egress of
these cells from the BM into the PB in a PLC-β2-dependent manner.
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